
US life sciences company Illumina’s proposed purchase of cancer test maker Grail Inc faces a lengthy EU antitrust investigation if it does not offer hefty concessions this week, people familiar with the matter said on Tuesday, July 13.
Illumina announced the US$8 billion cash-and-stock deal for cancer screening startup Grail last September under which it will buy out investors, including Amazon founder Jeff Bezos, to regain control of a company it spun out five years ago.
Last month, the European Commission opened a preliminary review into the deal, a decision Illumina is challenging in court because the deal does not meet the EU revenue criteria. It eventually decided to seek EU approval for the deal while waiting for the court ruling.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK to Boost Broadband Competition While Capping Openreach Charges, Says Ofcom
Mar 20, 2025 by
CPI
Singapore Competition Watchdog Yet to Receive Formal Notification on Grab-GoTo Merger
Mar 20, 2025 by
CPI
Crypto Exchange Kraken Buys NinjaTrader for $1.5 Billion
Mar 20, 2025 by
CPI
Airbnb Caught in Contradiction Over EU’s Digital Markets Act
Mar 20, 2025 by
CPI
Atkore Faces Shareholder Lawsuit Over Alleged Price-Fixing Scheme
Mar 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li